Sysmex's first-quarter progress exceeded expectations, but attention is shifting to the China business and portfolio review
AI summary card
Sysmex's first-quarter progress exceeded expectations, but attention is shifting to the China business and portfolio review
Strong installations of hematology equipment in the Americas drove FY3/27 first-quarter progress above expectations, prompting the company to raise its first-half outlook, while leaving second-half guidance unchanged due to uncertainty in the Chinese market and one-off costs related to the portfolio review. Goldman Sachs maintains its Buy view and 12-month target price of ¥1,950.
- Installations of the XN/XN-L series in the Americas were faster than the company expected, driving first-quarter progress above its initial guidance.
- Sales in China continue to decline, but performance remains broadly within the company's expectations.
- The company raised its first-half outlook but did not revise its second-half guidance.
- Six Chinese provinces piloted testing price standardization from July to August, and the company expects it may be rolled out nationwide by year-end.
- The XR series and the CN series in hemostasis are expected to begin contributing in the second half.
- The portfolio review policy is scheduled to be disclosed when second-quarter results are announced.
Report interpretation
Overview
This report summarizes the online investor conference call held by Goldman Sachs with Sysmex on August 21. The core view is that FY3/27 first-quarter progress was ahead of plan due to strong installations of hematology equipment in the Americas, but sustainability in the second half will still depend on new product contributions in the United States, changes in China's operating environment, and one-off costs arising from the portfolio review. Goldman Sachs maintains its Buy rating.
Core views
First-quarter performance was ahead of expectations, driven mainly by strong hematology instrument performance in the Americas. Installations of the XN/XN-L series in the Americas were faster than Sysmex itself expected and ahead of its initial guidance; other regions were broadly in line with expectations overall. The downward sales trend in the China business continues, mainly due to distributor inventory adjustments and the “minimum necessity principle,” but the related pressure has not exceeded the company's expected range. The company has incorporated the better-than-expected first-quarter performance into its FY3/27 first-half outlook and therefore raised its first-half guidance. However, second-half guidance remains unchanged. Reasons for the company's cautious stance include continued uncertainty in China's operating environment and potential one-off costs from the portfolio review. The relevant portfolio policy is scheduled to be announced with second-quarter results, so the current first-half improvement cannot be directly interpreted as a corresponding upward revision to the full-year earnings trajectory. Whether the U.S. business can sustain its strong performance is crucial for the second half. The report notes that installations of the XN/XN-L series may already have peaked, but Sysmex expects the XR series to begin contributing in the second half, while installations of the CN series in the hemostasis business are also expected to continue progressing in the second half. This means U.S. growth needs to transition gradually from the installation peak of existing hematology products to new contributions from the XR series and hemostasis products. Goldman Sachs also views growth in the U.S. and European hemostasis businesses, value-chain reforms, and portfolio adjustments as potential sources of improved profitability. The China business is another key area to monitor. Testing price standardization was piloted in six provinces from July to August, and Sysmex believes the system may be rolled out nationwide by year-end, at which point its actual pricing impact will become clearer. The company stated that testing prices are expected to be determined at the discretion of each province and set at appropriate levels, rather than adopting a nationally uniform minimum price. Therefore, the ultimate impact on the China business will depend not only on the pace of the nationwide rollout but also on actual pricing in each province and how it flows through to volumes, prices, and distribution channel adjustments. Goldman Sachs maintains its Buy rating and assigns a 12-month target price of ¥1,950. The target price is based on the global medical technology industry's FY3/28E average EV/EBITDA multiple of 12.0x, with a 20% discount applied to Sysmex. The report's positive thesis mainly derives from the potential for profitability improvement through growth in the U.S. and European hemostasis businesses, value-chain reforms, and portfolio optimization. Meanwhile, declining sales in China, changes in pricing policy, and portfolio review costs create uncertainty around the realization of earnings.
Analysis framework
Goldman Sachs first used information from the management conference call to compare actual first-quarter progress with the original guidance, then analyzed why first-half guidance was raised while second-half guidance remained unchanged. It subsequently broke down future earnings drivers by region, product series, and one-off costs, focusing on the U.S. product transition, China's pricing policy, and the portfolio review. For valuation, the report referenced the global medical technology industry's average forward EV/EBITDA multiple and applied a discount to Sysmex to determine the 12-month target price.
Methodology notes
Comparable EV/EBITDA valuation for the global medical technology industry
The report uses the global medical technology industry's FY3/28E average EV/EBITDA multiple of 12.0x as the valuation benchmark and then applies a 20% discount to Sysmex, deriving a 12-month target price of ¥1,950.
Decomposition of equipment installations, testing prices, and sales trends
The report separately examines equipment installation progress in the Americas, declining sales in China, and testing prices set by individual provinces to assess the differing impacts of product volume growth and pricing policy changes on performance.
Asset mapping & comparison
Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).
- Sysmex (6869.T)Strong installations of hematology instruments in the Americas drove first-quarter progress above expectations, but declining sales in China and changes in pricing policy continue to affect the future earnings trajectory.
- Strengths
- Installations of the XN/XN-L series in the Americas were faster than expected; the XR series and the CN series in hemostasis are expected to begin contributing in the second half; the U.S. and European hemostasis businesses, value-chain reforms, and portfolio optimization offer potential for improved profitability.
- Weaknesses
- Sales in China continue to decline, installations of the XN/XN-L series may already have peaked, and the portfolio review may also generate one-off costs.
- Comparison
- The target-price valuation uses the global medical technology industry's FY3/28E average EV/EBITDA multiple of 12.0x as the benchmark and applies a 20% discount to Sysmex.
- Risks
- Geopolitical and supply-chain changes, global healthcare cost-containment reforms, intensifying competition and price declines, exchange-rate fluctuations, inflationary pressure, and weakening capital expenditure.
Key data
- Investor conference call dateAugust 21Goldman Sachs held an online investor conference call with Sysmex
- Scope of China pilot6 provincesTesting price standardization was piloted from July to August
- China policy expectationMay be rolled out nationwide by year-endThe actual pricing impact is expected to become clearer after the nationwide rollout
- RatingBuyGoldman Sachs' current rating
- 12-month target price¥1,950Based on comparable industry valuation with a discount applied
- Valuation benchmarkFY3/28E EV/EBITDA 12.0xGlobal medical technology industry average
- Valuation discount20%Discount to the global medical technology industry's average valuation
- Portfolio review updateWhen second-quarter results are announcedThe company plans to disclose the relevant policy
Impact & implications
The report believes that the first-quarter outperformance improved first-half performance but is not yet sufficient to eliminate second-half uncertainty. Whether earnings momentum can continue depends on whether the XR and CN series can succeed the XN/XN-L installation peak, the actual outcome of China's testing price standardization, and whether value-chain reforms and portfolio adjustments can improve profitability after absorbing one-off costs.
Risks
- Geopolitical risks and supply-chain changes may affect operations.
- Healthcare system reforms, including global cost-containment policies, may reduce demand or prices.
- Intensifying competition, particularly the rise of local manufacturers in emerging markets, may create downside pricing risk.
- Exchange-rate movements may affect performance.
- A further increase in inflationary pressure may erode profitability.
- Weakening capital expenditure trends may suppress equipment demand.
What to watch
- Monitor changes in China's operating environment and the company's profitability trend in China.
- Monitor whether testing price standardization can be rolled out nationwide by year-end and the impact of actual provincial pricing on the business.
- Monitor whether the XR series can begin succeeding the XN/XN-L installation peak in the second half.
- Monitor the U.S. and European hemostasis businesses and the progress of CN series installations.
- Monitor the portfolio review policy and related one-off costs to be disclosed when second-quarter results are announced.
- Monitor whether value-chain reforms can improve profitability.